RG
ATYR

Redmile Group’s aTyr Pharma ATYR Stock Holding History

Redmile Group’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-134,642
Closed -$1.72M – 96
2018
Q2 		$1.72M Hold
134,642
– – 0.06% 67
2018
Q1 		$5M Sell
134,642
-129
-0.1% -$6.05K 0.19% 56
2017
Q4 		$6.6M Hold
134,771
– – 0.29% 54
2017
Q3 		$9.53M Buy
+134,771
New +$6.24M 0.47% 45

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return
MCIM
Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Redmile Group's ATYR Position: Q3 2018 in Review

Redmile Group sold out of aTyr Pharma (ATYR) in Q3 2018, closing a stake of 134,642 shares — an estimated $1.72M sold.

Redmile Group first reported a position in ATYR in Q3 2017 and held it in 4 quarters. The position peaked at $9.53M in Q3 2017. 31 funds tracked by Wall St. Rank hold ATYR as of Q3 2018.

  • Redmile Group reported no remaining aTyr Pharma position as of Q3 2018 after selling out during the quarter.
  • Redmile Group sold 134,642 aTyr Pharma shares in Q3 2018, an estimated $1.72M.
  • Redmile Group first reported a position in aTyr Pharma in Q3 2017 and held it in 4 quarters.
  • Redmile Group's aTyr Pharma position peaked at $9.53M in Q3 2017.
  • 31 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2018.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.